USS Investment Management Ltd Increases Position in Elevance Health, Inc. $ELV

USS Investment Management Ltd raised its holdings in Elevance Health, Inc. (NYSE:ELV) by 4.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,871 shares of the company’s stock after acquiring an additional 1,689 shares during the period. USS Investment Management Ltd’s holdings in Elevance Health were worth $11,093,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ELV. Kemnay Advisory Services Inc. purchased a new stake in shares of Elevance Health in the fourth quarter valued at approximately $31,000. J.Safra Asset Management Corp purchased a new position in Elevance Health during the fourth quarter worth approximately $32,000. ORG Partners LLC lifted its position in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Elevance Health during the fourth quarter worth $38,000. Finally, Dorato Capital Management acquired a new position in Elevance Health during the fourth quarter worth $41,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $415.51 on Thursday. The firm has a market cap of $90.23 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 2.19 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $426.98. The business’s fifty day simple moving average is $387.70 and its 200-day simple moving average is $350.26.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the company earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts forecast that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. The ex-dividend date was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Guggenheim raised their target price on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Jefferies Financial Group dropped their price objective on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Robert W. Baird lifted their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and boosted their target price for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $416.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.